Donidalorsen not checked
Ionis Pharmaceuticals, Inc. · ISIS 721744
FollowEvery change as it happens, and a Monday email
Trials
2 active
6 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Donidalorsen will be administered by subcutaneous (SC) injection.”In the company’s words, NCT07298447 on ClinicalTrials.gov
- Tested for
- Hereditary Angioedema, Hereditary Angioedema (HAE)
- Main trialPhase 3
- “The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).”In the company’s words, NCT05392114 on ClinicalTrials.gov
- Other names
- ISIS 721744 · IONIS-PKK-LRx
Other drugs for Hereditary Angioedema
- NavenibartAstria Therapeutics, Inc. · Phase 3
- DeucrictibantPharvaris Netherlands B.V. · Phase 3
- ADX-324ADARx Pharmaceuticals, Inc. · Phase 3
- BerotralstatBioCryst Pharmaceuticals · Phase 3
- NTLA-2002Intellia Therapeutics · Phase 3
- BW-20805Shanghai Argo Biopharmaceutical Co., Ltd. · Phase 2
Coming up2
- DecPhase 3 trial completes · ClinicalTrials.gov
- Jun 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2026 | A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | |
| Phase 3Recruiting | Jun 2029 | Donidalorsen Treatment in Children With Hereditary Angioedema | |
| Phase 3Completed | 9 Nov 2023 | OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE) | |
| Phase 2Completed | 4 Jan 2021 | A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema | |
| Phase 2Completed | 24 Jan 2025 | An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema | |
| Phase 1Completed | 9 Oct 2018 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026